Leandro Otero
Internal Medicine · Miami Lakes, FLNPI 1396785416
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $300, more than ten times the $13 reported in 2019.
Across 35 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$124
- Amgen$113
- AstraZeneca$103
- Sumitomo Pharma America, Inc.$69
- Abbott$62
- Boehringer Ingelheim$33
- plus $149 from 7 others
Across 171 payments — averaging $4887.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$836K
What the payments were for
- Food & beverage$653100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 7 | $124 |
| Amgen | 7 | $113 |
| AstraZeneca | 5 | $103 |
| Sumitomo Pharma America, Inc. | 3 | $69 |
| Abbott | 3 | $62 |
| Boehringer Ingelheim | 2 | $33 |
| Lilly USA, LLC | 2 | $31 |
| Bayer | 1 | $23 |
| Pfizer | 1 | $22 |
| Micro-tech Endoscopy USA, Inc. | 1 | $20 |
| Exact Sciences | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| Phadia US Inc. | 1 | $15 |
How this compares
$653 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SynjardyEmpagliflozin/Metformin Hcl | 197 | $147,564 |
| EliquisApixaban | 136 | $111,389 |
| JardianceEmpagliflozin | 114 | $104,064 |
| ProliaDenosumab | 52 | $90,219 |
| JanuviaSitagliptin Phosphate | 81 | $90,125 |
| OzempicSemaglutide | 82 | $88,131 |
| FarxigaDapagliflozin Propanediol | 92 | $81,206 |
| TradjentaLinagliptin | 87 | $68,428 |
| LinzessLinaclotide | 105 | $59,998 |
| EntrestoSacubitril/Valsartan | 62 | $50,580 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $39,206 |
| JanumetSitagliptin Phos/Metformin Hcl | 46 | $35,970 |
| MounjaroTirzepatide | 30 | $34,212 |
| XareltoRivaroxaban | 46 | $33,238 |
| GemtesaVibegron | 37 | $24,637 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSynjardy, Jardiance, Tradjenta, Synjardy Xr, Combivent Respimat | $33 | $346,425445 claims |
| PfizerEliquis, Premarin | $22 | $117,585150 claims |
| Novo NordiskOzempic, Rybelsus | $124 | $104,44297 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $103 | $103,633159 claims |
| AmgenProlia | $113 | $90,21952 claims |
| Lilly USA, LLCMounjaro, Trulicity | $31 | $50,35947 claims |
| Johnson & JohnsonXarelto | $18 | $33,23846 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $69 | $24,63737 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Miami Lakes
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.